Journal
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 16, Issue 9, Pages 949-960Publisher
TAYLOR & FRANCIS AS
DOI: 10.1080/14737159.2016.1211934
Keywords
Pharmacogenetic testing; implementation; provider education; personalized medicine; barriers
Categories
Funding
- NIGMS NIH HHS [R01 GM081416] Funding Source: Medline
Ask authors/readers for more resources
Introduction: Just as technology was the underlying driver of the sequencing of the human genome and subsequent generation of volumes of genome sequence data from healthy and affected individuals, animal, plant, and microbial species alike, so too will technology revolutionize diagnostic testing. One area of intense interest is the use of genetic data to inform decisions regarding drug selection and drug dosing, known as pharmacogenetic (PGx) testing, to improve likelihood of successful treatment outcomes with minimal risks.Areas covered: This commentary will provide an overview of implementation research of PGx testing, the benefits of point-of-care (POC) testing and overview of POC testing platforms, available PGx tests, and barriers and facilitators to the development and integration of POC-PGx testing into clinical settings. Sources include the published literature, and databases from the Centers for Medicaid and Medicare Services, Food and Drug Administration.Expert commentary: The utilization of POC PGx testing may enable more routine test use, but the development and implementation of such tests will face some barriers before personalized medicine is available to every patient. In particular, provider training, availability of clinical decision supports, and connectivity will be key areas to facilitate routine use.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available